Alzheimer’s disease is a progressive neurologic disorder, with symptoms gradually developing over multiple years. Symptoms often begin with mild cognitive impairment and, over multiple years, gradually lead to severe loss of cognitive function.

The slow progressing nature of the disease makes it challenging to demonstrate benefit of potential therapies. Specifically, both manufacturers and HTA bodies have found it difficult to assess and demonstrate the efficacy of potentially disease modifying therapies that aim to slow progression of neurodegenerative diseases such as Alzheimer’s.

However, a novel assessment method, focused on measuring the slowing of disease and resultant prolonging of time to disease progression has been proposed, leading to the question: how can this novel outcome measure support value demonstration and assessment?

This session will include perspectives from multiple stakeholders on:

• Why prolonging the time until progression is important and has been proven difficult to demonstrate to date
• How the novel measure can help in overcoming historical barriers in effect demonstration and assessment
• Its potential application to health economic models and HTA assessment

Sponsored by Novo Nordisk